EP
NTLA icon

Essential Partners’s Intellia Therapeutics NTLA Stock Holding History

Essential Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.49K Sell
147
-878
-86% -$12.3K ﹤0.01% 1885
2026
Q1 		$13.1K Buy
1,025
+551
+116% +$7.02K ﹤0.01% 1115
2025
Q4 		$4.26K Sell
474
-13
-3% -$179 ﹤0.01% 1495
2025
Q3 		$8.41K Buy
487
+16
+3% +$197 ﹤0.01% 1227
2025
Q2 		$4.42K Buy
+471
New +$3.87K ﹤0.01% 1086

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Essential Partners's NTLA Position: Q2 2026 in Review

Essential Partners reduced its Intellia Therapeutics (NTLA) stake by 86% in Q2 2026, selling an estimated $12.3K and leaving 147 shares worth $2.49K. The position accounts for ﹤0.01% of the portfolio, ranked #1885.

Essential Partners first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. The position peaked at $13.1K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Essential Partners held 147 shares of Intellia Therapeutics worth $2.49K as of Q2 2026.
  • Essential Partners sold 878 Intellia Therapeutics shares in Q2 2026, an estimated $12.3K.
  • Intellia Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1885 holding.
  • Essential Partners first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Intellia Therapeutics position peaked at $13.1K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.